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 Response to the reviewers from the authors:
We would like to thank the reviewers for their greatly appreciated review and their time and 
constructive criticism of our manuscript.
We have included all recommendations – and have only one suggestion from reviewer 2 left 
open for the decision by the editor.
We apologize for the many spelling mistakes and grammatical errors and made sure that in 
the current version, all errors were eradicated.
-Reviewer 1:
Overall, this is a useful set of guidelines to help vets to reach a correct diagnosis of 
DCM in the Doberman. The authors have done a thorough job of assimilating all the 
relevant clinical research on the topic. The images used to illustrate the guidelines 
are clear and of high quality.  
It is disappointing that there are several spelling mistakes, some omitted words and 
grammatical errors, as well as frequent misuse of punctuation throughout the 
manuscript. At times, this misuse of punctuation significantly interferes with the 
clarity of the statement being made e.g. Line 275 - 278. "Comment: Although the 
diagnosis of DCM can be established, if only one parameter is above the reference 
values, the accuracy of diagnosis improves, if both, diastolic and systolic 
measurements are above the cut-off values."
Two of the authors have English as a first language so there is no reason for this. A 
careful and thorough read-through of the manuscript should have been done by all 
authors prior to submission.
Lines 73-75. The statement "Ventricular premature complexes (VPCs) are a common 
finding in the occult phase of the disease, and about 30% of affected dogs die 
suddenly before the onset of congestive heart failure." needs referencing.
 added references
Lines 78-87. This section dealing with effect of gender is confusing and some 
statements seem contradictory. Please reword to improve flow and clarity for reader.
 amended
Lines 89-91. "Female dogs seem to have a slower progressive disease with VPCs 
detected with a 24h (Holter) as the only abnormality found, even in the older female 
dogs." The word ECG is missing after 24h. Rather than "slower progressive disease", 
it would be more correct to say "a slowly progressive form of the disease" or "slower 
disease progression". Are the authors saying that these female dogs never go on to 
develop echo changes (i.e. they just have an arrhythmogenic form of the disease) or 
that the echo changes just develop later in females than in the males? Please clarify 
what is meant by this statement for the reader.
 the paragraph was rewritten for clarification.
-Reviewer 2
  -
This is an interesting, timely and authoritative review, which is certainly appropriate for publication 
in JVC. However, I feel that there are some areas which would benefit from clarification and/or 
additional explanation and references, as detailed below, and I would be grateful if you would 
consider these as I think they would be of benefit to the reader. There are also many linguistic 
amendments/corrections required, as listed below:
CLARIFICATIONS / MODIFICATIONS:
 Line 1: Should the title perhaps be “… (ESVC) Proposed Screening Guidelines for …”?
 we leave this comment to the editor for decision. As the ESVC formed a committee and 
approved the guidelines, we feel that they are not only proposed, but approved and therefore 
we feel that “proposed” is not necessary
 Introduction (line 66 onwards): In an authoritative review such as this, I feel it would be 
appropriate to define “dilated cardiomyopathy”, with an appropriate reference(s), and 
similarly to define what you mean by the “occult phase” in this breed and to discuss how 
long how long the occult phase might last in this breed and how quickly it progresses, 
how variable this is (in addition to your discussion of the male/female differences in 
presentation)?
 amended. We added more information to the introduction, i.e. definitions and also more 
about the occult phase of the disease.
 Line 70: It is arguable whether idiopathic DCM occurs in the Boxer breed, although there 
is probably some geographical variation in this. Most cases of a DCM phenotype in 
Boxers are probably an end-stage of arrhythmogenic cardiomyopathy. Therefore I feel it 
might be better to omit the Boxer breed from this list.
 Boxer removed
 Lines 72-75: Can you provided a reference or references to back-up these statements, 
please?
 done
 Lines 100-101: “… in combination with the known rate of progression …” - can you 
expand on this please (see comment above under “Introduction”)?
 done
 Lines 118-119, Screening Frequency: This first sentence repeats what was said in the 
previous paragraph, and can probably be omitted?
 sentence removed
 Lines 148-170, Comments on special situations: It might be appropriate here to 
discuss the day-to-day variability of arrhythmia occurrence and frequency and to cite 
previous publications on this (even if these looked at other breeds)?
 done
 Line 176: “Basic guidelines” - can you clarify and/or insert a reference here please?
 added references
 Line 185: Reference [20] seems to be the same as reference [6]?
 changed and made into one
 Lines 298-300, also lines 685-686: Although commonly used (especially for HOCM in 
cats), “anterior” is not an approved term in veterinary anatomical nomenclature, and I feel 
that this journal, and an authoritative review such as this, should use only approved 
veterinary anatomical nomenclature? Therefore I would suggest replacing “anterior mitral 
valve leaflet” with “septal mitral valve leaflet” and replacing “anterior motion” with “motion 
towards the interventricular septum”, e.g. in lines 299-300 and685-686: “maximal motion 
(E-point) of the septal mitral valve leaflet towards the interventricular septum”?
 amended
 Lines 443 and 461: I assume “1 VPC” should be “1 VPC/5 minutes”?
 changed to 1 VPC/5 minutes
LINGUISTIC / TYPOGRAPHICAL AMENDMENTS:
All corrections/suggestions have been done – thank you again for the thorough review!
 Lines 30, 35 (in Abbreviation Table), 51 and 490: Please replace “Simpson Method of 
disc” with “Simpson’s method of discs” in all 4 occurrences
 Line 35 (in Abbreviation Table): cTnI is usually taken to mean cardiac troponin I, 
not circulating troponin I?
 Line 35 (in Abbreviation Table): VPC: You use the term ventricular 
premature complex (not contraction) in the body of the text?
 Line 43: European Society for Veterinary Cardiology - please use upper case for this title
 Line 53: Please replace “VPC” with “VPCs”
 Line 57: Please replace “guidelines provide also” with “guidelines also provide”
 Line 59: Please replace “but may” with “but which may”
 Line 69: Please replace “such as Doberman” with “such as the Doberman”
 Line 72: Please replace “Doberman Pinscher” with “Doberman Pinschers”
 Line 80: Please replace “was a disorder of primarily the” with “was primarily a disorder of 
the”
 Line 90: Please replace “slower” with “more slowly”
 Line 91: Please insert “ECG” after “(Holter)”
 Line 99: Please replace “and use both” with “and to use both”
 Line 100: Please replace “Given the disease” with “Given that the disease”
 Line 130: Please replace “reading” with “recording”
 Line 133: Please replace “software is notoriously inaccurate, manual 
adjustments” with “software are notoriously inaccurate and manual adjustments”
 Line 144: Please replace “as cut-off” with “as the cut-off”
 Line 145: Please replace “DCM, the authors” with “DCM, but the authors”
 Line 154: Please replace “diagnostic criterion” with “a diagnostic criterion” 
 Line 156: Please replace “less likely caused” with “less likely to be caused”
 Line 160: Please replace “12 months will” with “12 months with”
 Line 180: Please replace “or a systolic” with “or systolic”
 Line 191: Please replace “hypothyroid group, and progressive” with “hypothyroid group. 
Progressive”
 Line 197: Please replace “The SMOD is” with “SMOD is”
 Line 198: Please replace “The SMOD” with “The left ventricular volume determined by 
SMOD”
 Line 200: Please replace “should not visible” with “should not be visible”
 Line 202: Please replace “selected in the” with “selected from the”
 Lines 210-211: Please replace “reduce estimations in” with “reduced estimations of”
 Line 229: Please replace “long axis were” with “long axis view were”
 Line 234: Please replace “from right parasternal” with “from the right parasternal”
 Line 241: Please replace “at nadir” with “at the nadir”
 Line 245: Please replace “dogs that are difficult to achieve” with “dogs where it is difficult 
to achieve”
 Line 248: Please replace “and is preferred” with “and this is preferred”
 Line 249: Please replace “current” with “concurrent”
 Line 254: Please replace “criteria” with “criterion”
 Line 263: Please replace “used” with “using”
 Line 267: Please replace “obtained from right” with “obtained from the right”
 Line 303: Please replace “6,5” with “6.5”
 Line 305: Please replace “Simpson” with “SMOD”
 Lines 313 and 695: Please replace “fore shortening” with “foreshortening”
 Line 333: Please replace “Biomarker” with “Biomarkers”
 Line 334: Please replace “normal, but at” with “Normal. But at”
 Line 343: Please delete “stages”
 Line 344: Please replace “Study” with “study”
 Lines 345 and 346: Please replace “Doberman” with “Dobermans”
 Line 352: Please replace “90.4%) reduction” with “90.4%. Reduction”
 Line 360: Please replace “only had” with “had only”
 Line 366: Please replace “lab” with “laboratory”
 Line 368: Please replace “to 1st” with “to the 1st”
 Line 381: Please replace “group. Suggesting” with “group, suggesting”
 Line 383: Please delete “the current gold standard”, as this is repetitive here?
 Line 391: Please replace “years of using” with “years using”
 Line 401: Please replace “azotemia” with “renal dysfunction”, as azotemia is a laboratory 
finding, not a “disease process”?
 Line 411: Please replace “and is” with “and it is”
 Line 415: Please replace “This study was also reported, that” with “This study also 
reported that”
 Line 420: Please replace “and is therefore as for NT-proBNP is” with “and therefore, as 
for NT-proBNP, it is”
 Lines 430-431: Please replace “realize, that not cTnI can be increased not only in dogs 
with DCM” with “realize that cTnI is not only increased in dogs with DCM”
 Lines 433-434: Please replace “Therefore, as systemic diseases should be excluded, if 
increased” with “Therefore systemic diseases should be excluded if increased”
 Line 449: Please replace “goal” with “gold”
 Line 454: Please replace “a gallop rhythm” with “an audible gallop sound”
 Line 456: Please replace “Doberman” with “Dobermans”
 Line 477: Please replace “outline” with “outlined”
 Line 481: Please replace “genic” with “genetic”
 Line 518: Please add the full name of the second author (Horne, R.)
 Line 567-569: Reference [20] is the same as reference [6]? - please delete [20] and 
renumber subsequent citations.
 Line 597: Please add the full citation information for Reference [28]
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EPSS E-point to septal separation
ESV end-systolic volume
Holter 24-hour ambulatory 
electrocardiogram
LV left ventricle
LVIDd left ventricular internal diameter by 
M-Mode in diastole
LVIDs left ventricular internal diameter by 
M-Mode in systole
NT-proBNP N-terminal pro B-type natriuretic 
peptide
SI sphericity index
SMOD Simpson’s method of discs
VPC(s) ventricular premature complex(es)3435
36 Abstract3738 Background: Dilated cardiomyopathy (DCM) is the most common 39 cardiac disease in large breed dogs and is inherited in Doberman 40 Pinschers (Dobermans) with a high prevalence (58%).41 Objective: The European Society for Veterinary Cardiology (ESVC) 42 convened a task force to formulate screening guidelines for DCM in 43 Dobermans.44 Recommendations: Screening for occult DCM in Dobermans should 45 start at three years of age and use both Holter monitoring and 46 echocardiography. Yearly screening over the life of the dog is 47 recommended, as a one-time screening is not sufficient to rule out future 48 development of DCM. The preferred echocardiographic method is the 49 measurement of the left ventricular volume by Simpson’s method of discs 50 (SMOD). Less than 50 single ventricular premature complexes (VPCs) in 51 24 hours are considered to be normal in Dobermans, although detection 52 of any number of VPCs is cause for concern. Greater than 300 VPCs in 53 24 hours, or two subsequent recordings within a year showing between 54 50 to 300 VPCs in 24 hours is considered diagnostic of occult DCM in 55 Dobermans regardless of the concurrent echocardiographic findings. The 56 guidelines also provide recommendations concerning ancillary tests, that 57 are not included in the standard screening protocol, but which may have 58 some utility when recommended tests are not available or financially 59 untenable on an annual basis. These tests include assay of cardiac 60 biomarkers (Troponin I and N-Terminal pro-B type Natriuretic Peptide) as 61 well as a 5-minute resting electrocardiogram (ECG).62 Conclusion: The current guidelines should help to establish an early 63 diagnosis of DCM in Dobermans.
64 Introduction65 Cardiomyopathies are a heterogeneous group of diseases of the 66 myocardium associated with mechanical and/or electrical dysfunction that 67 usually (but not invariably) exhibit inappropriate ventricular hypertrophy or 68 dilation.[1] Dilated cardiomyopathy (DCM) is defined by the presence of 69 left ventricular dilation and contractile dysfunction, in the absence of 70 abnormal loading conditions and severe coronary artery disease.[2]71 Dilated cardiomyopathy is one of the most common cardiac diseases in 72 dogs and humans.[1, 3] In the dog, it primarily affects large and giant 73 breeds.[3] Some breeds, such as the Doberman, Newfoundland, 74 Portuguese Water dog, Great Dane, Cocker Spaniel, and Irish Wolfhound 75 exhibit a higher prevalence of DCM.[3-6] 76 DCM in Dobermans is an inherited, slowly progressive disease.[7-9] The 77 occult stage of the disease is characterized by evidence of morphologic or 78 electrical derangement in the absence of clinical signs of heart 79 disease.[10-14] The occult stage may last for several years, before 80 clinical signs develop.[8, 12] The morphologic abnormality consists of left 81 ventricular (LV) enlargement in systole and later in diastole.[15] 82 Ventricular premature complexes are a common finding in the occult 83 stage of DCM in Dobermans.[6, 9, 10, 12-14, 16-20] Sudden death, 84 caused by ventricular tachycardia-fibrillation, occurs during the occult 85 stage in at least 25 to 30% of affected dogs.[6, 9, 17] These 86 abnormalities, morphologic or electrical, may coexist or may be of 87 predominantly one form at any time during the occult stage.[6, 10, 17, 21, 88 22]89 A recent study showed a high cumulative prevalence (58.8%) of 90 cardiomyopathy in Dobermans in Europe [8], comparable to that reported 91 in the United States and Canada (45 and 63 %).a[21, 23]. The early 92 descriptions of DCM in Dobermans suggested that cardiomyopathy 93 predominantly affected males [13], and was later confirmed, although 94 females are also affected.a[11-13, 17, 21] One study showed that in 95 Dobermans, approximately 50% of male dogs and 33% of female dogs 96 develop DCMa, whereas another study found no gender difference.[24] 97 The most recent study showed that the disease is equally distributed in 
98 male and female dogs in Europe.[8] The difference in reported gender 99 distributions between earlier and later studies might be explained by the 100 inconsistent inclusion of a 24-hour electrocardiogram (Holter) or ECG as 101 part of the standard diagnostic screening in earlier studies. This could 102 explain the over-representation of dogs with morphological changes of the 103 heart, detectable by echocardiography.   Generally, male dogs are known 104 to show structural changes earlier than female dogs, which are detectable 105 with an echocardiogram. Males are therefore more likely to develop CHF 106 at an earlier age than female dogs, and likewise succumb from it 107 earlier.[8] Female dogs seem to have a more slowly progressive disease 108 with VPCs detected with a Holter as the only abnormality, even in older 109 female dogs. However, most female Dobermans will develop the typical 110 echocardiographically evident morphologic heart changes associated with 111 DCM at an older age, compared with male dogs.[8] 112 The average age of detection of occult DCM is between 5-7 years, but 113 some dogs are affected as young as 2 years of age. Therefore, it appears 114 appropriate to start screening for occult DCM in Dobermans at three 115 years of age and to use both Holter monitoring and echocardiography. 116 Given that the disease can develop over time in combination with the 117 known rate of progression over several years, screening should ideally be 118 repeated on an annual basis.[8, 12] In high-risk breeds, such as the 119 Doberman, yearly screening over the life of the dog is recommended but 120 can be cost prohibitive and requires a devoted owner.121 However, early detection of occult DCM can facilitate timely removal of 122 affected dogs from active breeding programs and early treatment for all 123 affected dogs leading to an increase in symptom free and overall 124 survival.[22, 25] Removal of affected dogs from breeding programs 125 should over time reduce the prevalence of DCM in Dobermans.126127 Recommendations128129 Screening Age
130 Screening should be started at 3 to 4 years of age. A one-time screening 131 is not sufficient to rule out future development of DCM, because the 132 disease is acquired and may develop with increasing age. 133134 Screening Frequency135 Yearly screening should be performed ideally in both male and female 136 dogs.  However, given male dogs involved in active breeding programs 137 have the potential to pass on the disease to a greater number of progeny 138 than female dogs if they are affected and not diagnosed, emphasis should 139 be on annual screening of male dogs that are involved in active breeding 140 programs.  Female dogs involved in breeding programs, pets and non-141 breeding dogs could be screened once every 2 years if budgetary 142 restrictions prevent annual screening.  143144 Holter Criteria145 It is essential that the Holter recording be of sufficient duration (at least 23 146 hours of readable recording), good quality and have an accurate analysis 147 verified by a cardiologist.  Holter reports generated by automated Holter 148 analysis software are notoriously inaccurate and manual adjustments are 149 always necessary. Inaccurate Holter reports can lead to both false 150 positive and false negative results both of which can have a significant 151 negative impact on breeders and pet owners.152153 Fewer than 50 single VPCs in 24 hours is considered to be normal in 154 Dobermans, although detection of any number of VPCs is cause for 155 concern.[6]  Greater than 300 VPCs in 24 hours, or two subsequent 156 recordings within a year showing between 50 to 300 VPCs in 24 hours is 157 considered diagnostic of occult DCM in Dobermans regardless of the 158 concurrent echocardiographic findings.[26] Many studies have used > 100 159 VPCs in 24 hours as the cut-off value for establishing a diagnosis of 160 DCM, but the authors believe the results of the most recent study [26] 161 should be the basis of current recommendations. 162163 Comments on special situations: 
164 1.) Holter examination shows 1 - 50 VPCs/24-hrs: In Dobermans, 165 detection of any number of VPCs is cause for concern, even if only 166 a few VPCs are detected in 24 hours (< 50 VPC/24-hrs). In these 167 cases, VPCs that have a short coupling interval (maximum velocity 168 of beat to beat coupling interval > 250/min) and complexity should 169 also be considered as an additional diagnostic criterion, as 170 couplets, triplets or single short runs of VPCs with a fast 171 instantaneous rate (>260/min) are potentially dangerous and are 172 less likely to be caused by myocardial damage secondary to other 173 systemic diseases. In these cases DCM cannot be ruled out and a 174 follow-up Holter examination should be performed within 3-6 175 months.176 2.) Holters showing between 50 - 300 VPCs in 24 hours and a follow-177 up Holter within 12 months with < 50 VPCs. Dogs in this category 178 remain a challenge as DCM cannot be definitively ruled out. In 179 these cases ongoing screening is strongly recommended.  180 3.) It is also important to acknowledge, that some dogs will have 181 normal echocardiograms but still have occult DCM diagnosed 182 based on the Holter results. Systemic diseases that could 183 potentially cause VPCs should always be excluded. Ventricular 184 escape complexes and accelerated idioventricular rhythms 185 (ventricular rate < 160 bpm) are not considered to be diagnostic for 186 DCM. The role of atrial premature contractions and atrial 187 tachycardia (excluding atrial fibrillation) in the diagnosis of DCM in 188 Dobermans is currently unknown. 189 4.) The day-to-day variability of VPCs in Dobermans is currently 190 unknown. In Boxer dogs and humans an individual day-to-day 191 variability of up to 85% was reported.[27, 28] 192193 Echocardiographic Criteria194 In general, the accuracy of the echocardiographic results will depend on 195 the quality of the examination. A complete echocardiogram including color 196 Doppler with a simultaneous ECG should be performed. Basic guidelines 197 should be followed including all measurements being made in triplicate for 
198 volume and 5 sequential (if possible) cardiac cycles for M-Mode.[29-31] 199 Congenital or acquired cardiac diseases other than DCM might also 200 cause volume overload, systolic dysfunction or both, and need to be 201 excluded accordingly.  Examples are patent ductus arteriosus, ventricular 202 septal defect, mitral valve dysplasia or myxomatous mitral valve 203 degeneration. Auscultation and color/spectral Doppler examinations 204 should be used to exclude these and other diseases. Hypothyroidism [32-205 34] and DCM [8, 35] are both common diseases in the Doberman. 206 Recently, it was shown that Dobermans with DCM have a 2.26 fold 207 increased risk to develop hypothyroidism.[35] However, hypothyroidism 208 does not seem to play a role in the etiology or progression of DCM in this 209 breed. In this study, hypothyroid dogs were receiving optimal thyroid 210 supplementation and there was no difference in cardiac size or number of 211 VPCs between the healthy and hypothyroid group. Progressive increase 212 in cardiac volume by SMOD and the number of VPCs was not different 213 between the groups.[35] 214215 Echocardiographic Measurements 216 Left ventricular volume by Simpson’s Method of Discs:217 Simpson’s method of discs is more sensitive than M-Mode to detect early 218 echocardiographic changes in Dobermans.[15] The left ventricular volume 219 determined by SMOD should be measured in the right parasternal long 220 axis 4-chamber view and in the left apical 4-chamber view (the aorta 221 should not be visible in either view) by tracing the endocardial border on 222 each selected image. The frame used to measure the End Diastolic 223 Volume (EDV) is selected from the frames around the onset of the QRS-224 complex, when the mitral valve is closed and the volume at its largest 225 (which may not be exactly at onset of the QRS complex) and the frame 226 used to measure the End Systolic Volume (ESV) is selected as the last 227 frame before mitral valve opening, typically after the end of the T wave, 228 where the volume is at its smallest (Figure 1). Both right parasternal and 229 left apical views should be measured and the larger volumes used, as this 230 reduces potential underestimation of the volume. The tendency for apical 231 foreshortening can easily lead to under-estimation of both ESV and EDV. 
232233 Cut-off values that indicate the presence of occult DCM based on left 234 ventricular volume estimates by SMOD are [15]:235236 EDV Index (EDVI)= EDV(ml) / BSA(m2): > 95ml/m2237 or238 ESV Index (ESVI)=ESV(ml) / BSA(m2): > 55 ml/m2239240 Body surface area (BSA) can be calculated from body weight (kg) using 241 this formula[36]:242 BSA = 10.1 x kg2/3 x 100243244 Left Ventricular M-mode Measurements:245 As M-mode is still commonly measured, the authors recommend use of 246 the following reference values if volume measurements by SMOD are not 247 available. However, if M-mode values are normal, but the volume index(s) 248 is/are enlarged, the authors recommend that the results should be based 249 on the volume index estimates, as they are more sensitive than M-mode.250251 M-mode reference values using the right parasternal long axis view were 252 obtained slightly differently in some studies.[22, 37] Whereas the 253 reference values from Wess et al.[37] were obtained from a right 254 parasternal long-axis four-chamber view, excluding the aorta (the same 255 view as used for the SMOD measurements), the reference values from 256 O’Grady[22] were obtained from the right parasternal long-axis 257 inflow/outflow view, with the aorta visible in the image (Figure 2a and 2b). 258 Others routinely use the right parasternal short-axis view at the level of 259 the chordae tendinae to obtain M-modes of the left ventricle (Figure 3), 260 ensuring the M-mode cursor bisects the left ventricular cavity. For all M-261 mode measurements, the left ventricular internal dimension in diastole 262 (LVIDd) is obtained ideally at the onset of the QRS and in the absence of 263 an ECG, the largest left ventricular internal dimension is selected.  The 264 left ventricular internal dimension in systole (LVIDs) is chosen at the nadir 265 corresponding to the peak downward motion of the interventricular 
266 septum along a single cursor, typically near the end of the T wave. Care 267 should be taken to minimize poor cursor alignment as this often leads to 268 overestimation of LVIDs. In dogs where it is difficult to achieve optimum 269 alignment, a common complaint in Dobermans, and for which volume 270 estimation is not possible, LVIDd and LVIDs can be acquired from 2 271 dimensional images and this is preferred over a poor M-mode image. 272 Although concurrent measurements from all views are most likely similar, 273 there is currently no study available comparing all 3 methods. However, 274 O’Grady adapted his long-axis derived M-mode reference range for LVIDs 275 for the short axis method and the short-axis cut-off value for LVIDs was 276 used in the Protect study as an inclusion criterion. Therefore, when using 277 M-mode reference values generated by different studies, the studies 278 reported measurement method should ideally be used. One study did 279 compare the accuracy of diagnosis of occult DCM in Dobermans using M-280 mode measurements and volume as estimated by SMOD and reported 281 that SMOD (sensitivity 100 %, specificity 99%) was superior to M-mode 282 using both O’Grady’s (sensitivity 89%, specificity 99%) and Wess’s 283 reported M-mode reference ranges (sensitivity 90%, specificity 89%). [37] 284 Both M-Mode measurements in that study were obtained from the right 285 parasternal long axis using the right parasternal long-axis four-chamber 286 view, excluding the aorta.287288 Cut-off values that indicate the presence of occult DCM based on M-289 mode as described by Wess [37] (obtained from the right parasternal long 290 axis 4-chamber view, Figure 2A):291292 LVIDd (male any weight) > 48 mm293 LVIDd (female any weight) > 46 mm294 or295 LVIDs (male and female any weight) > 36 mm296297 Comment: Although the diagnosis of DCM can be established if only one 298 variable is above the reference values, the accuracy of diagnosis 
299 improves if both, diastolic and systolic measurements, are above the cut-300 off values. 301302 Cut-off values that indicate the presence of occult DCM based on M-303 mode as described by O’Grady [22] (right parasternal long axis M-mode 304 using the inflow/outflow view, Figure 2B):305306 LVIDd >0.1749 x body weight (kg) + 40.3 mm and / or307 LVIDs > 0.1402 x body weight (kg) + 26.7 mm308309 Cut-off values that indicate the presence of occult DCM based on M-310 mode as described by O’Grady and adapted for short axis [25] (right 311 parasternal short axis M-mode or 2 dimensional, Figure 2C):312313 LVIDs > 0.1402 x body weight (kg) + 35.3 mm314315 Other secondary echocardiographic measures of systolic left 316 ventricular function317318 E-point to septal separation (EPSS) 319 E-point to septal separation measurement is obtained from the right 320 parasternal long axis view or short axis view at the level of the tip of the 321 septal mitral valve leaflet. E-point to septal separation is the distance of 322 the maximal early diastolic motion (E-point) of the septal mitral valve 323 leaflet to the interventricular septum (Figure 3). A recent study evaluated 324 EPSS in the role of detecting occult DCM in Dobermans and showed that 325 EPSS > 6.5mm is a valuable additional variable for the diagnosis of DCM, 326 which when added to M-mode measurements can improve sensitivity and 327 specificity to levels that are similar to volume estimates by SMOD.[38]328329330 Sphericity index (SI)331 The geometrical shape, i.e. the sphericity of the LV can be assessed by 332 comparing left ventricular length in diastole obtained from a right 
333 parasternal long axis or left parasternal apical four-chamber view 334 (obtained at end diastole as per the SMOD with caution to avoid apical 335 foreshortening) (Figure 4) to the M-mode LVIDd. The SI is calculated by 336 dividing the length of the LV in diastole by the width of the LV in diastole.  337 An SI <1.65 is associated with an increased sphericity and is considered 338 abnormal according to the ESVC guidelines.[39] A study in Dobermans 339 reported, that an SI < 1.65 is also the best cut-off to identify occult DCM in 340 Dobermans. However, because the sensitivity and specificity of SI alone 341 was not very good (sensitivity 86.8 %, specificity 87.6%) when compared 342 to volume estimates using SMOD and EPSS, its inclusion as a 343 recommended parameter in screening protocols for Dobermans is not 344 warranted.[38]345346347348 Ancillary tests, currently not included as standard screening tests:349350 The following tests are currently not recommended for screening 351 purposes, but may have some utility when recommended tests such as 352 echocardiography and a Holter are not available or financially untenable 353 on an annual basis.354355 Biomarkers such as cardiac troponin I (cTnI) [40] or N-Terminal pro B-356 type natriuretic peptide (NTproBNP) [41, 42] might be abnormal in some 357 dogs, in which Holter and echocardiography are still normal. But at this 358 time, there is not sufficient evidence that they can replace Holter and or 359 echocardiography, but they might be valuable additional tests. N-Terminal 360 pro B-type natriuretic peptide values > 500 pmol/L can predict 361 echocardiographic changes consistent with occult DCM and the corollary 362 is also true in that Dobermans with an NT-proBNP < 500 pmol/L are 363 unlikely to have contemporaneous echocardiographic evidence of occult 364 DCM.365366 N-Terminal pro B-type natriuretic peptide (NT-proBNP)
367 Screening for occult disease is one of the most promising areas of blood 368 sample-based biomarker research. In one study including 328 369 Dobermans, plasma NT-proBNP concentration was significantly higher in 370 Dobermans with DCM, including those with occult DCM, diagnosed by 371 echocardiography alone or both echocardiography and a Holter, than in 372 healthy dogs.[41] The NT-proBNP assay was not clinically useful to detect 373 disease in dogs presenting only with ventricular arrhythmias. In this study 374 the best cut-off value for the prediction of echocardiographic 375 abnormalities indicative of DCM was > 550 pmol/L (sensitivity 78.6%, 376 specificity 90.4%). Reduction of the cutoff value to > 400 pmol/L 377 increased the sensitivity to 90.0%, while specificity decreased to 75.0%. 378 In a second study, the combined use of an NT-proBNP cutoff value > 457 379 pmol/L and a Holter recording led to detection of occult DCM with a 380 sensitivity of 94.5%, specificity of 87.8%, and overall accuracy of 381 91.0%.[42] Similar to the aforementioned study [41], NT-proBNP 382 concentration was most accurate for detection of occult DCM when 383 Dobermans had echocardiographic changes indicative of occult DCM, but 384 had poor accuracy for identification of dogs that had only ventricular 385 arrhythmias. Both of these studies were performed using the 1st 386 generation assay without use of the protease inhibitor tubes for sample 387 collection (but immediately frozen at -80 C and then sent frozen for batch 388 analysis). N-Terminal pro B-type natriuretic peptide values degrade over 389 time, if the samples are not frozen and shipped cooled. This is especially 390 important if the 1st generation assay is used. One laboratory is offering 391 now a second-generation assay, which does not require protease inhibitor 392 tubes and can be posted unfrozen.  As this assay was designed to give 393 similar results to the 1st generation assay, and was utilized in one study 394 (abstract ECVIM) of 449 Dobermans screened with a combination of 395 echocardiography and a 3-minute ECG.b This study reported that a cutoff 396 of > 548 pmol/L had a sensitivity of 100% and a specificity of 80% to 397 detect the characteristic echocardiographic morphologic changes of DCM 398 with or without concurrent evidence of VPCs on a 3-minute ECG. These 399 findings are not significantly different from those reported on earlier 
400 generations of this assay and together emphasize the role of NT-proBNP 401 testing in the Doberman.b  402 Despite its reported usefulness, the NT-proBNP assay does not replace 403 recommended gold standard diagnostic procedures such as 404 echocardiographic examination, for which the sensitivity and specificity of 405 detecting left ventricular dysfunction can be as high as 97%.[15]406 One study reported a longitudinal design that included follow-up 407 examinations allowing the retrospective identification of a group of dogs 408 (last-normal) that were determined to be normal according to gold-409 standard diagnostic methods (echocardiogram and Holter) at the time of 410 NT-proBNP sample collection, but went on to develop DCM within 1.5 411 years of this evaluation.[41]  Plasma NT-proBNP concentrations were 412 significantly increased in this group, compared with concentrations in the 413 control group, suggesting that DCM was detected in this group by NT-414 proBNP measurement earlier than was possible with a combination of 415 echocardiography and a 24 hour Holter.[41] Validation of these results in 416 other studies would be needed to make screening recommendations 417 solely on blood based testing. 418419420 NT-proBNP Recommendations 421 NT-proBNP appears to be especially useful to predict echocardiographic 422 changes in Dobermans and it might be reasonable to screen dogs > 3 – 4 423 years using the NT-proBNP test. This type of testing could be considered 424 when the owner cannot afford the expense of echocardiography and 425 Holter recording. There is not sufficient evidence to support NT-proBNP 426 testing alone in screening Dobermans when the other established tests 427 are available and affordable. In addition, it cannot be used alone to 428 establish a diagnosis on which to base a recommendation to begin 429 therapy.[43]430 As with any diagnostic test, certain limitations and considerations must be 431 recognized when using the NT-proBNP assay. Circulating NT-proBNP 432 concentration can be affected by concurrent disease processes such as 433 renal dysfunction, pulmonary hypertension, sepsis, or systemic 
434 hypertension as well as incorrect blood sample handling or use of the 435 assay in inappropriate patients. Lastly, if repeated sampling is done as 436 part of a screening protocol normal day-to-day variation should be taken 437 into account.[44] 438439 Troponin I440 Circulating cardiac troponin I has been demonstrated to be a highly 441 specific and sensitive marker for myocardial cellular damage in humans 442 and animals. The primary value of cTnI as a cardiac biomarker in humans 443 is to detect myocardial infarcts [45]. It is reported to be significantly 444 elevated in Dobermans with DCM.[40] Dogs with more advanced stages 445 of the disease had the highest concentrations of cTnI. It was not only 446 elevated in Dobermans with echocardiographic changes, but also in dogs 447 that had only VPCs. This study also reported that cTnI was elevated in a 448 very early stage of the disease (”last normal group” or “incipient group” as 449 discussed above). Dogs in the “last normal” or “incipient” group had 450 significantly higher cTnI values compared to control dogs. The best cut-off 451 for cTnI to predict DCM using the Immulite assay was > 0.22 ng/mL 452 (sensitivity 79.5% and specificity 84.4%) and therefore, as for NT-453 proBNP, it is a valuable additional diagnostic test to screen for 454 cardiomyopathy in Dobermans when the gold standard is not available. It 455 likewise suffers from similar limitations as outlined previously for NT-456 proBNP.[40] However, there is not sufficient evidence to support that this 457 test could replace conventional methods such as echocardiography and 458 Holter examinations.[40] Lastly, cTnI concentrations have also been 459 shown to have an additional value for risk assessment of sudden cardiac 460 death in Dobermans with an enlarged heart, using a cut-off value of > 461 0.34 ng/mL.[46] 462 It is important to realize that cTnI may be increased in dogs with systemic 463 conditions or myocarditis and the cardiomyocyte injury indicated by 464 increased cTnI is not specific for DCM.[40, 47-53]. Therefore systemic 465 diseases should be excluded if increased cTnI levels are detected.466 There are different cTnI assays available and the test results might not be 467 completely comparable. Ultrasensitive tests may detect even earlier 
468 changes compared with this study and may lead to lower cut-off values. 469 This needs to be investigated in future studies. One study in 449 470 Dobermans reported a cTnI cut-off off > 0.139 ng/mL (ADVIA Centaur 471 CP® Ultra-TnI; lower limit of detection of 0.006 ng/mL) had a 100 472 sensitivity and 79% specificity to detect the characteristic 473 echocardiographic morphologic changes of DCM with or without 474 concurrent evidence of VPCs on a 3-minute ECG.b 475476 In House-ECG477 An in-house ECG cannot be used to replace a Holter examination. 478 However, > 1 VPC/5 minutes is highly suggestive that > 100 VPCs will be 479 recorded in 24 hours if a Holter is performed.[54] Therefore, when Holter 480 and/or echocardiography are not available, or an owner wants to first 481 have other tests performed, in order to be more convinced that further 482 examinations (Holter, echocardiography) are necessary a combination of 483 the following tests should be performed. However, it should be 484 emphasized that these tests are not validated as sole screening tests, do 485 not represent the gold standard screening tests and cannot be used to 486 establish a diagnosis with which to make recommendations to begin 487 treatment. 488489 Clinical examination:490 A systolic murmur over the left apex, an audible gallop sound on 491 auscultation, weak pulse quality, an arrhythmia or pulse deficits are all 492 suspicious findings in Dobermans and represent a strong indication to 493 proceed with additional tests. 494 Biomarker:495 NTproBNP result > 500 pmol/L496 cTnI > 0.22 ng/mL497 ECG: 1 VPC/5 minutes (or more) or atrial fibrillation are considered 498 abnormal499500 If any of the above tests are abnormal, a further work-up including Holter 501 examination and echocardiography is strongly recommended.
502503 Genetic tests for DCM in Dobermans504 The genetic test based on the 16-bp deletion in the canine pyruvate 505 dehydrogenase lipoamide kinase isozyme 4 (PDK4) might be useful in the 506 USA [55], but may not be useful in Europe, as one study showed no 507 association between PDK4 and DCM in a European study [56].508 The results of genetic tests should not be used in place of standard 509 screening. The absence of a genetic mutation known to be associated 510 with a heritable disease such as DCM in Dobermans does not ensure the 511 dog will never go on to develop DCM. In addition, the identification of a 512 genetic mutation does not guarantee the dog will go on to develop DCM, 513 and should not be considered a death sentence, but should be followed 514 up with screening as outlined above. It is also clear there may be 515 important regional differences even within a single breed and single 516 disease. The real value of identifying genetic markers associated with 517 heritable diseases may be to take them into consideration when selecting 518 breeding pairs. Identification of genetic markers of heritable diseases in 519 dogs and cats remains an active area of investigation. 520521 Conclusions:522 Yearly screening over the life of the dog is recommended, as a one-time 523 screening is not sufficient to rule out future development of DCM. 524 Screening for occult DCM in Dobermans should start at three years of 525 age and use both Holter monitoring and echocardiography. The preferred 526 echocardiographic method is the measurement of the left ventricular 527 volume by Simpson’s method of discs (SMOD). Greater than 300 VPCs in 528 24 hours, or two subsequent recordings within a year showing between 529 50 to 300 VPCs in 24 hours is considered diagnostic of occult DCM in 530 Dobermans regardless of the concurrent echocardiographic findings. 531 Ancillary tests, including biomarkers (cTnI and NT-proBNP) as well as in-532 house ECG recordings could be helpful in situations where the standard 533 recommended tests are not available.534535 Footnotes
536 a.) O'Grady M.R., Horne R. The prevalence of dilated cardiomyopathy 537 in Doberman Pinschers: A 4,5 year follow-up (abstract). J Vet 538 Intern Med 1998;12:199.539 b.) Gordon S.G., Estrada A.H., Braz-Ruivo L., Drourr L., Morris N., 540 O’Grady M.R., Boggess M.M. Evaluation of NTproBNP, High 541 Sensitivity Troponin I and PDK4 for the Detection of Occult DCM: A 542 Prospective Study in 449 Doberman Pinschers. (Abstract ECVIM 543 Forum 2015) J Vet Intern Med 2016;30:365.544
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757 Figures758759 Figure 1:760 Left ventricular volume by Simpson’s Method of Discs. The SMOD should 761 be measured in the right parasternal long axis 4-chamber view and in the 762 left apical 4-chamber view (the aorta should not visible in either view) by 763 tracing the endocardial border on each selected image. The End-Diastolic 764 Volume (EDV) is selected around the onset of the QRS-complex, when 765 the mitral valve is closed and the volume largest (which might not be 766 exactly where the QRS complex starts. The End-Systolic Volume (ESV) is 767 selected typically near the end of the T wave, where the volume is 768 smallest. Both right parasternal and left apical views should be measured.769770 Figure 2:771 Different methods used to generate reference intervals for M-Mode:772 2a: right parasternal long-axis four-chamber view, excluding the aorta (the 773 same view as used for the SMOD measurements) , as used for the 774 reference values from Wess et al.[37]775 2b: right parasternal long-axis inflow/outflow view, with the aorta visible in 776 the image, as used for the reference values from O’Grady [22]777 2c: right parasternal short-axis view at the level of the chordae tendinae to 778 obtain M-modes of the left ventricle.779780 Figure 3:781 EPSS measurement is obtained from the right parasternal long axis view 782 or short axis view at the level of the tip of the septal mitral valve leaflet. 783 EPSS is the distance of the maximal motion (E-point) of the septal mitral 784 valve leaflet to the interventricular septum during the rapid filling stage of 785 diastole786787 Figure 4:788 Sphericity index (SI)789 The geometrical shape, i.e. the sphericity of the left ventricle (LV) can be 790 assessed by comparing left ventricular length in diastole obtained from a 
791 right parasternal long axis or left parasternal apical four-chamber view 792 (obtained at end diastole as per the SMOD with caution to avoid apical 793 fore shortening) to the M-mode LVIDd. The SI is calculated by dividing the 794 length of the LV in diastole by the width of the LV in diastole.  




